Liarozole
Small molecule
GSKLiarozole is one of 9 small molecule programs targeting Ichthyosis. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Ichthyosis
#DrugCompanyPhaseTrials
1Cosentyx
NovartisApproved
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Approved
Accutane
CConrado Roberto Hoffmann Filho
Phase 2
Garamycin
SSchering-Plough
Phase 2
Stelara
Johnson & JohnsonPhase 1
Imsidolimab
VVanda Pharmaceuticals
Phase 2
Monolaurin
CCellegy Pharmaceuticals
Phase 3
CD5789 (trifarotene)
MMayne Pharma International Pty Ltd
Phase 2
Liarozole
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Liarozole. EMBL-EBI & Wellcome Sanger Institute.
- [4]